Brentuximab ( DrugBank: Brentuximab )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| 51 | Scleroderma | 2 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02533570 (ClinicalTrials.gov) | July 2015 | 9/7/2015 | Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus | A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus | Systemic Lupus Erythematosus | Drug: Brentuximab vedotin;Drug: Placebo | Seagen Inc. | NULL | Terminated | 18 Years | N/A | All | 20 | Phase 2 | United States |
51. Scleroderma
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03198689 (ClinicalTrials.gov) | May 7, 2019 | 14/6/2017 | Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis | A Pilot Study of Adcetris Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma) | Diffuse Cutaneous Systemic Sclerosis | Drug: Brentuximab Vedotin | Lawson Health Research Institute | Seagen Inc. | Recruiting | 18 Years | N/A | All | 11 | Phase 2 | Canada |
| 2 | NCT03222492 (ClinicalTrials.gov) | September 20, 2017 | 17/7/2017 | Brentuximab Vedotin for Systemic Sclerosis | Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI) | Diffuse Cutaneous Systemic Sclerosis;Scleroderma;dcSSc | Biological: Brentuximab Vedotin;Biological: Placebo | National Institute of Allergy and Infectious Diseases (NIAID) | Immune Tolerance Network (ITN);Seagen Inc.;PPD;Rho Federal Systems Division, Inc. | Recruiting | 18 Years | 70 Years | All | 24 | Phase 1/Phase 2 | United States;Canada |